The Live Nagpur
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Crime
  • Entertainment & Lifestyle
  • Featured
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary

The Live Nagpur

  • Home
  • Nagpur City
  • Politics
  • Business
  • Nagpur Education
  • Entertainment
  • Nagpur Sports
  • Health
  • Vidarbha
  • Crime
  • Obituary
Business

Innoplexus Announces Major Findings in Potential Combination Therapies for COVID-19

by TLN Team March 27, 2020March 27, 2020
written by TLN Team March 27, 2020March 27, 2020
Innoplexus Announces Major Findings in Potential Combination Therapies for COVID-19

Today, Innoplexus AG announced some first results in its artificial intelligence-enabled search for a COVID-19 antiviral treatment.

Innoplexus began by scanning data on previously approved drugs for off-label potential in treating COVID-19, using its proprietary artificial intelligence (AI) and big data platform to generate actionable insights from hundreds of terabytes of structured and unstructured public data, drawing from sources ranging from private research databases to social media.

Innoplexus processed hundreds of studies covering thousands of patients. Its AI-platform was used to analyze data coming from expression data, molecular pathways, drug binding affinities, and clinical trials published.

One of the most prominently upcoming drugs identified as Hydroxychloroquine, for which more than 200 reports were found. Hydroxychloroquine is a derivative of Chloroquine that has both antimalarial and anti-inflammatory activities. While some smaller studies with Hydroxychloroquine alone showed mixed results in fighting COVID-19, Innoplexus’ proprietary trial prediction engine suggests overall more limited response rates (response being defined as a shorter and less severe disease trajectory than would be seen in the absence of the drug) for ongoing and upcoming clinical trials for Hydroxychloroquine alone.

However, Hydroxychloroquine is a potential and immediately available treatment cost-effective option, although it could have major side effects for specific patient groups. The long-approved drug has been widely used as a prophylaxis for Malaria and as a treatment for autoimmune diseases like rheumatoid arthritis and lupus. It is on the World Health Organization’s list of essential medicines and has been prescribed five million times in the US in 2017 alone. Given that Hydroxychloroquine is out of patent and easy to produce, it is among the most promising stand-alone treatment options especially in emerging markets, where the cost of treatment is expected to be a significant factor.

In an effort to improve the efficacy of treatments, Innoplexus used its AI platform to analyze drug pathways and interactions in their vast self-learning Knowledge Graphs – built over the entire universe of available biological data – to identify targets for human and virus proteins. Additionally, Innoplexus’ AI evaluated the clinical potential of medications approved for other diseases to identify promising drug combinations that work synergistically to interrupt disease mechanisms.

These findings suggest that a combination of Hydroxychloroquine – or Chloroquine – with several previously approved drugs might yield better results than any drug administered alone. This hypothesis needs to be further evaluated in in-vitro and in -vivo research.

According to the AI-based analysis, a combination of Chloroquine and Tocilizumab, a drug approved to treat severe rheumatoid arthritis respectively. Tocilizumab is thought to interrupt the process of ‘cytokine release syndrome’ (CRS), a form of serious inflammatory response that can occur as a complication of COVID-19.

This first algorithm-based AI analysis of the data ocean also suggested that Chloroquine combined with Remdesivir, an antiviral drug developed by Gilead to treat Ebola, might also be effective. However, Remdesivir has not been approved yet for any indication and some first study results of Remdesivir alone showed limited efficacy. Our analysis suggests higher efficacy for a combination.

Finally, Hydroxychloroquine combined with Clarithromycin or Plerixafor, a semisynthetic macrolide antibiotic derived from erythromycin and an antiretroviral for HIV respectively, could be an option to be evaluated further. Plerixafor appears to act as an immunostimulant, while Clarithromycin seems to be able to block the internalization of the virus into host cells during the early phase of infection. Despite safety concerns regarding Plerixafor, it might have a positive effect in certain clinical settings.

Innoplexus is in the process of validating all of these combinations in vitro and in vivo studies.

“Our analysis has shown a good basis for allowing these combinations of previously approved drugs in off-label-use with further evaluation,” said Dr. Gunjan Bhardwaj, Founder and CEO of Innoplexus. “As such, we recommend that governments and regulators take bold action and remove hurdles in order to substantially lower the incidence of critical and lethal cases of COVID-19. Confirmatory clinical studies should be done in parallel.”

To further facilitate and expedite research, Innoplexus is offering its AI-based Clinical Trial Designer and Launch support solutions free of charge to any biotech or pharma company working on solutions to COVID-19.

Finally, Innoplexus has also generated potential candidates for novel molecules using its deep generative models powered by NVIDIA’s DGX-1 supercomputers.

“This is crucial in order to be prepared for future viral strains,” added Dr. Bhardwaj.

The two novel molecules target a specific virus protein and stop the growth of the virus. Initial results from in silico ADMET predictions and docking simulations showed improved efficacy compared to existing drugs. Additional tests are in progress.

0 comment
FacebookTwitterLinkedin
TLN Team

previous post
COVID-19: NEET, JEE exams postponed till May
next post
COVID-19 mass hit, Maha gov decides to release 11,000 prisoners

You may also like

Deepika Padukone now reigns Spices Category!

March 1, 2021

GST issues, malpractices, CAIT to begin nation-wide agitation...

March 1, 2021

Ranjit Singh new chairman of CII Vidarbha Zone

February 28, 2021

CAIT call Bharat Vyapar Bandh was successful- Bandh...

February 26, 2021

City traders give lukewarm response to CAIT’s ‘Bharat...

February 26, 2021

NVCC supports CAIT demands for Bharat Vyapar Bandh...

February 24, 2021

Bank account, properties to be seized for violation...

February 24, 2021

Institute of Chartered Accountants of India to set...

February 24, 2021

LIC launches digital application-ANANDA

February 22, 2021

“Opportunities to MSME- Initiatives by the National Small...

February 22, 2021

Leave a Comment Cancel Reply

Save my name, email, and website in this browser for the next time I comment.



Trending News

  • In10 Media Network’s New Hindi General Entertainment Channel ‘Ishara – Zindagi Ka Nazara’

    March 1, 2021
  • Sony launches digital voice recorder PCM-A10 for supreme sound, superior recording

    March 1, 2021
  • NSE triples its investment to INR 900 crores in technology infrastructure over last 3-4 years

    February 27, 2021
  • UltraTech’s Awarpur unit donates computers in Zilla Parishad schools

    February 27, 2021
  • Govt extends existing COVID-19 guidelines till Mar 31

    February 26, 2021

Important Links

  • Politics
  • Crime
  • Business
  • Education
  • Entertainment
  • Sports

Available on Playstore & Coming Soon on Appstore

Search

March 2020
M T W T F S S
« Feb   Apr »
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Sign-Up Form

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Footer Logo
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Crime
  • Entertainment & Lifestyle
  • Featured
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary
  • Privacy Policy
  • Disclaimer
  • Cookie Policy
  • Terms Of Use
  • Advertise with Us
  • Work with us
  • Contact Us

© 2020 - The Live Nagpur . All Rights Reserved.